

Winald R Gerritsen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7712827/publications.pdf>

Version: 2024-02-01

33
papers

5,543
citations

471509

17
h-index

454955

30
g-index

34
all docs

34
docs citations

34
times ranked

8077
citing authors

#	ARTICLE	IF	CITATIONS
1	Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. <i>New England Journal of Medicine</i> , 2017, 376, 1015-1026.	27.0	2,677
2	Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 700-712.	10.7	1,280
3	Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 40-47.	1.6	577
4	Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 1051-1061.	1.6	174
5	Potential of the conditionally replicative adenovirus Ad5-Delta24RGD in the treatment of malignant gliomas and its enhanced effect with radiotherapy. <i>Cancer Research</i> , 2002, 62, 5736-42.	0.9	142
6	Dendritic Cell Cancer Therapy: Vaccinating the Right Patient at the Right Time. <i>Frontiers in Immunology</i> , 2018, 9, 2265.	4.8	107
7	Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 1579-1587.	1.6	97
8	Strong vaccine responses during chemotherapy are associated with prolonged cancer survival. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	83
9	Favorable overall survival in stage III melanoma patients after adjuvant dendritic cell vaccination. <i>Oncolmmunology</i> , 2016, 5, e1057673.	4.6	67
10	Differential Effects of Combined Ad5-Î”24RGD and Radiation Therapy in <i>In vitro</i> versus <i>In vivo</i> Models of Malignant Glioma. <i>Clinical Cancer Research</i> , 2007, 13, 7451-7458.	7.0	47
11	Autologous monocyte-derived DC vaccination combined with cisplatin in stage III and IV melanoma patients: a prospective, randomized phase 2 trial. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 477-488.	4.2	42
12	Convection Enhanced Delivery of the Oncolytic Adenovirus Delta24-RGD in Patients with Recurrent GBM: A Phase I Clinical Trial Including Correlative Studies. <i>Clinical Cancer Research</i> , 2022, 28, 1572-1585.	7.0	36
13	Pembrolizumab (pembro) versus investigatorâ€™s choice of paclitaxel, docetaxel, or vinflunine in recurrent, advanced urothelial cancer (UC): 5-year follow-up from the phase 3 KEYNOTE-045 trial.. <i>Journal of Clinical Oncology</i> , 2021, 39, 4532-4532.	1.6	32
14	Prognostic Value of Novel Liquid Biomarkers in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide: A Prospective Observational Study. <i>Clinical Chemistry</i> , 2020, 66, 842-851.	3.2	25
15	Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials. <i>Clinical Cancer Research</i> , 2022, 28, 2050-2060.	7.0	21
16	Two-year follow-up from the phase 3 KEYNOTE-045 trial of pembrolizumab (pembro) vs investigatorâ€™s choice (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (UC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 410-410.	1.6	19
17	Management of gastrointestinal (GI) toxicity associated with nivolumab (NIVO) plus ipilimumab (IPI) or IPI alone in phase II and III trials in advanced melanoma (MEL).. <i>Journal of Clinical Oncology</i> , 2017, 35, 9523-9523.	1.6	18
18	Adjuvant dendritic cell vaccination induces tumor-specific immune responses in the majority of stage III melanoma patients. <i>Oncolmmunology</i> , 2016, 5, e1191732.	4.6	17

#	ARTICLE	IF	CITATIONS
19	Planned survival analysis from KEYNOTE-045: Phase 3, open-label study of pembrolizumab (pembro) versus paclitaxel, docetaxel, or vinflunine in recurrent, advanced urothelial cancer (UC).. Journal of Clinical Oncology, 2017, 35, 4501-4501.	1.6	17
20	Clinical experience with PSMA-Actinium-225 (Ac-225) radioligand therapy (RLT) in end-stage metastatic castration-resistant prostate cancer (mCRPC) patients.. Journal of Clinical Oncology, 2018, 36, 344-344.	1.6	11
21	Preclinical exploration of combining plasmacytoid and myeloid dendritic cell vaccination with BRAF inhibition. Journal of Translational Medicine, 2016, 14, 88.	4.4	10
22	A prospective phase I multicentre randomized cross-over pharmacokinetic study to determine the effect of food on abiraterone pharmacokinetics. Cancer Chemotherapy and Pharmacology, 2019, 84, 1179-1185.	2.3	9
23	The Oncology Data Network (ODN): A Collaborative European Data-Sharing Platform to Inform Cancer Care. Oncologist, 2020, 25, e1-e4.	3.7	9
24	A tipping point in cancer-immune dynamics leads to divergent immunotherapy responses and hampers biomarker discovery. , 2021, 9, e002032.		6
25	Responsiveness to Immune Checkpoint Inhibitors Is Associated With a Peripheral Blood T-Cell Signature in Metastatic Castration-Resistant Prostate Cancer. JCO Precision Oncology, 2020, 4, 1374-1385.	3.0	6
26	The Oncology Data Network (ODN): Methodology, Challenges, and Achievements. Oncologist, 2020, 25, e1428-e1432.	3.7	3
27	Overall survival using radium-223 (Ra223) in metastatic castrate-resistant prostate cancer (mCRPC) patients with and without DNA damage repair (DDR) defects.. Journal of Clinical Oncology, 2020, 38, 121-121.	1.6	3
28	Homologous recombination repair deficient prostate cancer represents an immunologically distinct subtype. OncoImmunology, 2022, 11, .	4.6	3
29	Assessing Metastatic Disease in Advanced Prostate Cancer: It's Time to Change Imaging. European Urology, 2017, 71, 93-95.	1.9	2
30	Whole Blood Transcriptome Profiling Identifies DNA Replication and Cell Cycle Regulation as Early Marker of Response to Anti-PD-1 in Patients with Urothelial Cancer. Cancers, 2021, 13, 4660.	3.7	2
31	Development and validation of a bioanalytical assay on LC/MS/MS to quantify enzalutamide and N-desmethylenzalutamide in human plasma.. Journal of Clinical Oncology, 2016, 34, 330-330.	1.6	1
32	Analytical challenges in quantitative analysis (LC/MS/MS) of abiraterone: A validated assay to determine abiraterone in human plasma.. Journal of Clinical Oncology, 2016, 34, 329-329.	1.6	0
33	Association of concomitant use of acid reducing agents in full-dose vemurafenib users with risk of progression in BRAF V600 mutation-positive unresectable or metastatic melanoma patients: A retrospective cohort study.. Journal of Clinical Oncology, 2017, 35, 9540-9540.	1.6	0